MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®GlobeNewsWire • 09/22/26
Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without ModificationGlobeNewsWire • 09/14/26
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/02/26
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/26
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/27/26
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound DebridementGlobeNewsWire • 04/13/26
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionGlobeNewsWire • 04/02/26
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/12/26
MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast InjuriesGlobeNewsWire • 12/10/25